Clinical trials: Diabetes Mellitus Type II
Diabetes Mellitus, Type 2
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec…
- Trial name
- NCT07112339
- Testing
- Insulin icodec, Basal insulin analogues
- Where
- 75 sites in Canada, Germany and 1 more
- Volunteers
- 586 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Essential Hypertension Complicated by Type 2 Diabetes Mellitus
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type…
- Trial name
- NCT02079805
- Testing
- Azilsartan, Telmisartan
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single Dose Study of PF-04991532 in Healthy Subjects
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01102673
- Testing
- PF-04991532
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Vietnam.
- Trial name
- DiabCare Asia (NCT02066766)
- Testing
- No treatment given
- Where
- Vietnam
- Volunteers
- 1,631 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Forxiga Tablets Specific Clinical Experience Investigation for Elderly
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga) in elderly patients.
- Trial name
- NCT02200627
- Where
- 46 sites in Japan
- Volunteers
- 1,724 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age.
- Trial name
- NCT00035542
- Testing
- Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
- Where
- 50 sites in United States
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
This study in Germany is designed to compare the effects of twice-daily exenatide plus metformin and twice-daily premixed human insulin aspart plus metformin with respect to glycemic control, as measured by HbA1c, combined with…
- Trial name
- NCT00434954
- Testing
- exenatide twice daily (BID), premixed insulin aspart twice daily (BID)
- Where
- 39 sites in Germany
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus(T2DM)
A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
The primary objective of this study is to assess the pharmacokinetic parameters of saxagliptin and metformin in healthy male Chinese subjects.
- Trial name
- SAXA (NCT01755494)
- Testing
- Saxagliptin 5 mg, Metformin XR 500 mg, Mertformin XR 2 x 500 mg
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic…
- Trial name
- NCT00641056
- Testing
- Exenatide Once Weekly, Insulin Glargine
- Where
- 75 sites in United States, Australia and 14 more
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT01103622
- Testing
- AZD1656, Digoxin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Trial name
- NCT00367445
- Testing
- Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus - Poor Control
A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once Weekly in Antidiabetic Treatment-naive Patients…
- Trial name
- NCT07058545
- Testing
- CJC-1134-PC Injection
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).
- Trial name
- NCT00272077
- Testing
- Insuline glargine
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants…
- Trial name
- NCT02009488
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Diabetes Mellitus, Type 2
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of…
- Trial name
- LEAD-2 (NCT00318461)
- Testing
- liraglutide, metformin, glimepiride
- Where
- 190 sites in Argentina, Australia and 18 more
- Volunteers
- 1,091 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Japanese Phase 1 Multiple Ascending Dose Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01515202
- Testing
- BMS-823778
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM.
- Trial name
- NCT01497522
- Testing
- Vildagliptin
- Where
- 20 sites in Japan
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients
This is an observational study in which data from people with type 2 diabetes mellitus (T2DM) in Germany who use the medical app "myTherapy" are studied.
- Trial name
- SMART-Finder (NCT05552339)
- Testing
- Finerenone (Kerendia, BAY94-8862), Type 2 DM drugs
- Where
- Germany
- Volunteers
- 348 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.